USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: GLSYNTHESIS, INC.
City: WORCESTER
State: MA
Zip+4: 01605-
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $3,464,856.00 21
SBIR Phase II $21,038,688.00 12
STTR Phase I $100,000.00 1

Award List:

COMMERCIAL PRODUCTION OF DINUCLEOTIDE PHOSPHORAMIDITES

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Chen, Jan L
Award Amount: $99,543.00

GRAM+ ANTIMICROBIALS TARGETED TO DNA POLYMERASE III

Award Year / Program / Phase: 1998 / STTR / Phase I
Agency: HHS
Research Institution: University of Massashusetts
Principal Investigator: Wright
Award Amount: $100,000.00
RI Contact: N/A

NOVEL DRUG FOR URINARY INCONTINENCE

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Chen, Jan L
Award Amount: $100,000.00

DRUGS TO PREVENT RECURRENT HERPESVIRUS INFECTIONS

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Wright, George E
Award Amount: $100,000.00

ANTIANGIOGENESIS BY THYMIDINE PHOSPHORYLASE INHIBITORS

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: George E. Wright
Award Amount: $104,259.00
Abstract:
Not Available Digital imagery offers a number of advantages over traditional photography. With few or no moving parts digital cameras can be rugged. The constant evolution of semiconductor technology makes them small and powerful. The CAM+ takes advantage of these factors, and our own expertise in… More

N/A

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $0.00

N/A

Award Year / Program / Phase: 1999 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $1,114,537.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Paul M. Tarantino
Award Amount: $145,787.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: George E. Wright
Award Amount: $0.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase II
Agency: HHS
Principal Investigator: George E. Wright
Award Amount: $364,035.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jan L. Chen
Award Amount: $0.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase II
Agency: HHS
Principal Investigator: Jan L. Chen
Award Amount: $515,752.00

FLUOROSOME TECHNIQUE FOR DRUG PERMEABILITY STUDIES

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Karsten A. Holm
Award Amount: $262,854.00
Abstract:
A major problem in drug discovery is the need to predict candidates with optimal disposition properties in animals. Good oral absorption is often a key property, and the Caco-2 intestinal cell model, routinely used for predicting human oral availability of drugs, has disadvantages. These include… More

HYBRID MOLECULES DESIGNED TO ENHANCE ANTIBIOTIC ACTIVITY

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: George E. Wright
Award Amount: $0.00
Abstract:
here is a crisis in the management of diseases caused by multi- antibiotic resistant strains of Gram-positive bacteria. This work will result in the development of new antibiotic drugs acting on a novel target. It is both technologically innovative and highly relevant to human health. Phase I of… More

NEW DERMAL ANESTHETICS

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Vincent B. Ciofalo
Award Amount: $0.00
Abstract:
Dermal anesthetics are used to anesthetize the skin of patients for various reasons, ranging from minor cutaneous surgery and needle inserts to skin grafts. The dermal anesthetic market is dominated by a single preparation, called EMLA (AstraZeneca), which consists of a eutectic mixture of lidocaine… More

NEW DERMAL ANESTHETICS

Award Year / Program / Phase: 2002 / SBIR / Phase II
Agency: HHS
Principal Investigator: Vincent B. Ciofalo
Award Amount: $1,927,195.00
Abstract:
Dermal anesthetics are used to anesthetize the skin of patients for various reasons, ranging from minor cutaneous surgery and needle inserts to skin grafts. The dermal anesthetic market is dominated by a single preparation, called EMLA (AstraZeneca), which consists of a eutectic mixture of lidocaine… More

DNA POLYMERASE IIIE, A NEW ANTIBIOTIC TARGET

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: George E. Wright
Award Amount: $307,138.00
Abstract:
DESCRIPTION (provided by applicant): There is a worldwide crisis in management of drug-resistant bacterial infections. In particular Gram-positive (Gram+) bacteria such as Staphylococcus aureus, Enterococcus fecalis and Enterococcus fecium are increasingly resistant to traditional antibiotics.… More

Antiviral Drugs for Treatment of Herpes B Infections

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: George E. Wright
Award Amount: $253,746.00
Abstract:
DESCRIPTION (provided by applicant): Monkey Herpes B virus (BV) has been reported to cause lethal infections in humans. BV is indigenous to macaque monkeys used in research, and is a potential group B bioterrorism agent. Human disease is characterized by vesicular eruptions on the skin or mucous… More

Fluorosome Technique for Drug Permeability Studies

Award Year / Program / Phase: 2004 / SBIR / Phase II
Agency: HHS
Principal Investigator: Karsten A. Holm
Award Amount: $933,529.00
Abstract:
DESCRIPTION (provided by applicant): We have validated a novel method, the "Fluorosome-trans Technique", to measure membrane permeabilities of drugs. The results for 47-marketed drugs show high correlation with human oral absorption. This method employs specific fluorophore-vesicle preparations,… More

Non-Sedating Atropisomeric Drugs for Atopic Disease

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jan L. Chen
Award Amount: $225,752.00
Abstract:
DESCRIPTION (provided by applicant): The present project's goal is to develop oral medications for the treatments of atopic dermatitis, asthma and allergic rhinitis. SAR studies have produced two lead compounds that show increased potency and markedly reduced side affects compared with previously… More

Preclinical development of a novel antibacterial for Clostridium difficile diseas

Award Year / Program / Phase: 2005 / SBIR / Phase II
Agency: HHS
Principal Investigator: George E. Wright
Award Amount: $1,851,181.00
Abstract:
DESCRIPTION (provided by applicant): In phase I we have identified a new class of active-site directed inhibitors of DMA polymerase HIE, a novel replicative enzyme in Gram+ bacteria. The compounds, 7-substituted-N2-(3,4-dichlorobenzyl)guanines "DCBGs", are potent enzyme inhibitors, and selected… More

In vitro substrate assay for multi-drug resistance

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Donald L. Melchior
Award Amount: $140,384.00
Abstract:
DESCRIPTION (provided by applicant): One criterion of a successful drug is its ability to reach its target site. A major reason that candidates are ineffective is that the compounds do not enter cells or cross the barriers that exist between the various compartments of the body, e.g. intestinal… More

High Throughput Membrane-Water Partition Coefficients

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: George E. Wright
Award Amount: $255,352.00
Abstract:
DESCRIPTION (provided by applicant): A key molecular property used for drug screening and design is the partition coefficient, measured by partitioning between an organic solvent and water, but more commonly calculated with algorithms based on octanol:water-derived hydrophobicity constants. However,… More

Hybrid Molecules Designed to Enhance Antibiotic Activity

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: George E. Wright
Award Amount: $2,844,916.00
Abstract:
DESCRIPTION (provided by applicant): The worldwide resurgence of antibiotic resistant Gram-positive bacteria, especially Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium and Streptococcus pneumoniae, has stimulated discovery of novel agents that can selectively attack new bacterial… More

Non-Sedating Atropisomeric Drugs for Atopic Diseases

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Jan Chen
Award Amount: $2,464,307.00
Abstract:
DESCRIPTION (provided by applicant): In our program to develop non-sedating ketotifen analogs, we found that norketotifen (NORK) and N-hydroxyethyl-norketotifen (HENK) had significant antiasthmatic and anti-inflammatory activity but less sedation and antimuscarinic activity than ketotifen. These… More

Novel Antithrombotic Diadenosine Tetraphosphate Analogs

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ivan B. Yanachkov
Award Amount: $333,166.00
Abstract:
DESCRIPTION (provided by applicant): There is significant interest in development of new antiplatelet agents as antithrombotic drugs that act directly and reversibly, avoiding documented drawbacks of the current drug of choice, clopidogrel. A synthetic ATP analog, which is a potent antagonist of… More

Diadenosine Boranotetraphosph(on)ates as Antithrombotic Drugs

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ivan B. Yanachkov
Award Amount: $299,670.00
Abstract:
DESCRIPTION (provided by applicant): There is significant interest in development of new antiplatelet drugs that will act directly and reversibly, avoiding clear problems with the current drug of choice, clopidogrel. Diadenosine P1,P4-tetraphosphate (Ap4A) and its phosphonate and thiophosphonate… More

Rapid in vitro substrate assay for the multi-drug resistance p-glycoprotein

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $1,078,178.00
Abstract:
DESCRIPTION (provided by applicant): The ability of a drug to reach and penetrate its intended target within the body is critical to its success in treating disease. However, drug efflux proteins such as p-glycoprotein (pgp) actively pump hydrophob ic drugs away from target tissues and are… More

Novel Antithrombotic Diadenosine Tetraphosphate Analogs

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: Ivan B. Yanachkov
Award Amount: $1,548,117.00
Abstract:
DESCRIPTION (provided by applicant): Phase I resulted in our discovery of low nanomolar level inhibitors of ADP-induced human platelet aggregation, with a unique mechanism of action, that warrant further development as first-in-class antithrombotic drugs. We developed a novel, efficient, high yield… More

Analogs of GTP as novel inhibitors of bacterial c-di-GMP-synthesizing enzymes

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: George E. Wright
Award Amount: $299,848.00
Abstract:
DESCRIPTION (provided by applicant): The bacterial second messenger c-di-GMP (cyclo-(GMP)2) is responsible for inducing certain pathogenic bacteria to form biofilms, complex structures of one or more bacterial strains that resist conventional antibiotics a nd are associated with numerous infectious… More

Preclinical development of a novel antibacterial for Clostridium difficile diseas

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: George E. Wright
Award Amount: $3,000,000.00
Abstract:
ABSTRACT  Among inhibitors of Gram+ DNA polymerases IIIC and IIIE, several compounds are active against multiple strains of the anaerobic Gram+ bacterium Clostridium difficile (Cdiff). The compounds appear to be selective for Cdiff compared with other Gram+ anaerobes and aerobes, and a lead… More

Oral prodrug of a novel antiviral that blocks neuronal reactivation of HSV

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Sofya Dvoskin – 508-754-6700
Award Amount: $300,000.00
Abstract:
DESCRIPTION (provided by applicant): There is no cure for herpes simplex virus (HSV) latent infections of neurons, and the possibility of asymptomatic reactivation and simultaneous transfer of infectious virus via mucous membranes is a significant drawback of current therapies. We have pioneered… More

Healing of Diabetic Ulcers with Gaseous Nitric Oxide Generated from Room Air

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Wei-chu Xu – 508-754-6700
Award Amount: $237,357.00
Abstract:
DESCRIPTION: Androgen action is the net result of opposing pathways of steroid biosynthesis and metabolism. It is now widely recognized that testosterone (T) is an androgenic precursor of the more potent 5 -dihydrotestosterone (DHT), produced by 5 -reductase type 2. Circulating T and DHT also serve… More

Novel Antithrombotic Diadenosine Tetraphosphate Analogs

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Ivan B. Yanachkov – 508-754-6700
Award Amount: $3,396,941.00
Abstract:
DESCRIPTION: Undesired platelet activation can be result of many common pathologies or interventions. Arterial thrombosis and the acute ischemic events that follow, such as myocardial infarction and stroke, are among the leading causes of death, incapacitation, and rising health care costs in the… More